Stockreport

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]

VYNE Therapeutics Inc.  (VYNE) 
PDF Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 23%. Looking ahead, revenue is forecast to grow 94% p.a. on average [Read more]